logo
The Physicians Really Are Healing Themselves, With Ozempic

The Physicians Really Are Healing Themselves, With Ozempic

New York Times10-02-2025

When Dr. C. Michael Gibson, a cardiologist at Harvard Medical School, goes to heart disease meetings, he can't help noticing a change.
'We will sit around at dinner and halfway through the meal, we will simultaneously push our plates away,' Dr. Gibson said. 'We look at each other and laugh and say, 'You, too?''
They share what is becoming an open secret: They tried for years to control their weight but are now taking the new obesity drugs manufactured by Eli Lilly and Novo Nordisk.
Dr. Robert Califf, the former chief of the Food and Drug Administration, says he hardly recognizes his colleagues. So many are now so thin.
'Looking good,' he says he tells his fellow cardiologists at conferences and meetings.
There are no studies documenting the percentage of doctors taking the drugs. But physicians 'are a good litmus test for drugs that are highly effective,' Dr. Califf said. If doctors who read the papers describing clinical-trial results are rushing to get a new drug, that is an indication that it's really promising.
His colleagues' use of Wegovy and Zepbound reminds him of the use of statins, drugs that lower cholesterol, in their early days. Cardiologists, who were most familiar with the consequences of high cholesterol levels, were among the first to take the drugs in large numbers.
Many newly thin cardiologists and diabetes specialists, like so many of their patients, had risk factors for heart disease. Or their blood sugar was creeping up. Or just the physical strain of carrying excess weight made everyday life burdensome. They say they like their new looks but also their new health and energy. In a way, they feel like members of a club.
Four years ago, Dr. Darren McGuire, a cardiologist at the University of Texas Southwestern, was struggling with obesity and Type 2 diabetes. Then he started taking Ozempic, the Novo Nordisk diabetes drug that is sold under the name Wegovy for obesity. He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity.
He lost 30 percent of his weight and got his blood sugar under control. Now, he said, he's 'feeling better than ever.'
He is also struck by the number of colleagues who seem to be using the medications.
'People look pretty different,' said Dr. McGuire, who is on advisory boards for Novo Nordisk and Eli Lilly. 'It is amazing.' He described one prominent diabetes specialist, Dr. John Buse of the University of North Carolina, who 'has shrunk away.'
Not quite, Dr. Buse said. But, he said, 'I lost 25 percent of my body weight and it totally changed my life.' He had struggled with his size since childhood, gaining, losing and then gaining weight again.
When he dieted, he 'would get crazy hungry,' Dr. Buse said. With Wegovy, he said, his weight dropped effortlessly until he reached his goal. Then his appetite returned, which was scary. But instead of regaining pounds, he maintained a consistent weight as he continued to take the drug.
Like other patients, he found that taking the drugs eliminated most of his desire to drink alcohol. Before he started Wegovy, he often would have two or three drinks with dinner. Now he has one, or none.
Dr. Buse, who is a consultant for Novo Nordisk and Eli Lilly, said that he did not often ask people at diabetes meetings if they were taking one of the drugs but that 'there are people who have changed a lot.' He said he would 'bet dollars to doughnuts' that they were on weight-loss medication.
Some cardiologists are still 'in the closet,' Dr. Gibson said.
One is a cardiologist in Boston. She said the person who prescribed Ozempic for her was also a female cardiologist who was taking it. She asked not to be identified because she had told only a few people she was on the drug. She was trying to keep her medical information private, although she suspected that her colleagues might have guessed. She added that she was pretty sure she knew who else was taking one of the drugs.
'Yes, you can definitely tell,' she said. 'And when you go to dinners, you can definitely see. We eat, like, an eighth of our meal. I know what's going on here.'
The doctors know they are privileged.
At first, Dr. Buse's health insurance paid for his Wegovy. But soon North Carolina stopped paying for obesity drugs for state employees, so he paid out of pocket. With a list price of $1,349 a month, it was a major expense.
Then, at a meeting in Europe, he asked a colleague to prescribe Wegovy for him and got a six-month supply. Dr. Buse was able to purchase Wegovy for a quarter of what it cost in the United States.
The doctors also know how to advocate for themselves and navigate the medical system better than many of their patients do.
Dr. McGuire's insurer initially declined to pay for his drugs. 'I had to appeal,' he said. 'I have a relationship with a primary care physician and know when to keep pushing.'
His insurer agreed to pay.
Dr. Gibson said that his insurer had paid without issue and that he wanted to discuss his decision to take Wegovy openly. (He recently switched to Lilly's Zepbound, also covered by his insurance, because it elicits an even greater weight loss.)
'A lot of people are of the mind-set that it is shameful, that it is cheating to use a drug,' Dr. Gibson said.
But the obesity drugs changed his life, he said: 'It's the greatest thing I ever did.'
And even Zepbound, powerful as it is, is just the beginning, Dr. Gibson said.
'There are 120 new agents coming along,' he noted, referring to drugs in clinical trials. 'I look forward to ones that may have even better safety and effectiveness.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut
Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut

Yahoo

time26 minutes ago

  • Yahoo

Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut

Omada Health, Inc. (NASDAQ:OMDA) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share. On Thursday, Omada Health priced its initial public offering of 7.9 million at $19/share. The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. The company raised $150 million in its IPO. Reuters reported Omada Health's valuation hit $1.28 billion. Omada's revenue increased 57% in the first quarter of 2025 to $55 million from $35.1 million a year earlier, according to its prospectus. For 2024, revenue rose 38% to $169.8 million from $122.8 million the previous company's net loss narrowed to $9.4 million in the first quarter from $19 million a year ago. Omada launched its initial virtual program in diabetes prevention and weight health in 2012. The company delivers virtual care between doctor visits, providing an engaging, personalized, and integrated experience for members designed to improve their health while delivering value for employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of programs. According to its S-1 filing, the company had 2,000 customers and more than 679,000 members enrolled in one or more programs as of 31 March. Omada says it has supported more than 1 million members since its launch. The company expanded its virtual care programs to target prediabetes, hypertension, and musculoskeletal conditions. The company estimates that about 20 million people have benefits coverage for one or more Omada programs. According to the company's S-1 filing, this represents about 14% of the self-insured insurance market, 9% of the fully insured market, 1% of the Medicare Advantage market, and 1% of the PBM market. Wall Street Journal, citing President Wei-Li Shao, writes that Omada leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have sparked a renewed focus on health problems that can stem from obesity. GLP-1s are expected to be a significant tailwind as more employers are rolling out reimbursement plans for the drugs, CEO Sean Duffy told WSJ. Omada, which signs contracts with employers to offer as a benefit to their workers, aims to be a complementary service that helps patients navigate taking GLP-1s. Omada's IPO is the second digital health IPO in weeks following an extended drought for the industry. In May, digital physical therapy startup Hinge Health Inc. (NYSE:HNGE) debuted on the New York Stock Exchange. Hinge Health priced its IPO of 13.7 million shares at $32 per share. Price Action: OMDA stock is trading lower by 0.43% to $22.90 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Obesity Startup Metsera Shares Rise on Early-Stage Trial Results
Obesity Startup Metsera Shares Rise on Early-Stage Trial Results

Bloomberg

time3 hours ago

  • Bloomberg

Obesity Startup Metsera Shares Rise on Early-Stage Trial Results

Metsera Inc. 's shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would allow patients to go from weekly to monthly dosing. In a small, early-stage trial, Metsera's drug — called MET-233i — helped patients shed up to 8.4% of their weight in 36 days, the company said in a statement. The drug also stayed around in the body longer, meaning it has the potential to be taken less frequently than shots made by Novo Nordisk A/S and Eli Lilly & Co.

The Philly Special: 7pm dinner rez is the real winner
The Philly Special: 7pm dinner rez is the real winner

Axios

time3 hours ago

  • Axios

The Philly Special: 7pm dinner rez is the real winner

Just call it the Philly Special — most of us make dinner reservations for the early evening. Why it matters: Eating earlier in the day supports your body's natural clock — boosting metabolism and improving sleep, experts say. Driving the news: 7 o'clock dinners are our jam in Philly, with 19.6% of reservations booked in the 7-8pm hour compared to 17.5% for the rest of the country, per Resy data shared with Axios. Some of us are late Birds, with a higher share of reservations booked after 9pm than those sleepyheads everywhere else. Zoom out: Nationally, dinner times have shifted earlier since the pre-pandemic years. What they're saying: If you have a later dinner, but eat the same amount, "that by itself leads to an increase in cravings, changes in appetite hormones and fewer calories burnt across the waking hours," Frank Scheer, Harvard Medical School professor and Medical Chronobiology Program director, tells Axios.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store